Dresden, Germany / Kyiv, Ukraine, 26 February 2025 – Enamine, Chemspace, and PharmAI Discovery GmbH (PAID) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy. This collaboration brings together the success of Enamine’s discovery biology and chemistry competencies, Chemspace’s expertise in ultra-large chemical space exploration for drug discovery, and PAID’s AI-powered molecular discovery platform to identify and develop promising drug candidates faster and with greater precision, both for conventional and molecular radiotherapy and radio diagnostics. Specific modulator molecules labeled with a radioisotope can target various cancers highly selective and locate such cancer cells for diagnosis or deliver precisely radiation for their destruction. The recent successes in radioligand therapy (RLT) in the clinic, regulatory breakthrough therapy designations, product approvals, and broad technology advancements catalyzed considerable growth in this field, evident by new company formations and market expansion. This partnership allows for the critical acceleration of the Design-Make-Test-Analyze cycle of potential compounds for RLT, saving time towards new treatments for cancer patients with still unmet medical needs.
We are excited to be a part of this collaboration that gives us the opportunity to use our unique approaches to exploration of ultra-large chemical spaces like Enamine REAL™ and Freedom Space™ as a source of qualified starting points for discovery projects as well as follow-up studies, especially in hit-to-lead and lead-optimization,
said Olga Tarkhanova, CEO at Chemspace. We are expecting to design, identify, and develop promising drug candidates not just faster but also with greater precision because of dovetailing our competencies.
Dresden, Saxony in Germany is one of the world leading centers in radiopharmacy evident by the approval of transformative radiotheranostics,
said Yurii Moroz, Vice President of Sales and Marketing of Enamine. The combination of such expertise by PharmAI Discovery, catalyzed by AI/ML, with Chemspace’s abilities to effectively explore the immensely exploded chemical space, plus Enamine’s unfaltering commitment to synthesize and evaluate with high probability rapidly novel make-on-demand compounds, driven by medicinal chemistry and disease biology, constitutes a powerful R&D alliance to not just create but advance transformative drug candidates for diagnosis and therapy of patients with serious diseases as cancer.
Andreas Fintelmann, CEO of PAID, shared: AI and chemistry are two powerful tools, but they work best when combined. By working with Enamine and Chemspace, we’re enhancing our ability to identify promising drug candidates and bring them to clinical development much faster.
Dr. Mahmood Nazari, COO of PAID, added: One of our key goals is to further improve our AI predictions by integrating more experimental validation. This collaboration ensures that every step — from AI-driven screening to real-world testing — strengthens the reliability and success of our discoveries.